The new mens range debuted at a VIP fashion show in Palm Beach last week, and will arrive in stores in February for the ...

Those punchy dresses started to outsell the juice ... displayed alongside several one-of-a-kind archival Lilly Pulitzer ...

In a sweet team-up between two iconic Florida brands, TooJay’s Deli and Lilly Pulitzer have created a limited-edition Lemon Coconut Cake to celebrate Lilly Pulitzer’s 65th anniversary. You can now ...

"Slim Aarons: Gold Coast," an exhibition that highlights Aarons' years of work in Palm Beach and how that work intertwined with Palm Beach icon Lilly Pulitzer, kicks off the Ann Norton Sculpture ...

A Charlotte architecture firm representing resort-wear maker Lilly Pulitzer has filed exterior design plans for a proposed boutique at Mount Pleasant Towne Centre. The upscale apparel retailer is ...

RISES OVER 1.6% AT IT’S HIGH FOR THE DAY AFTER EARLY DROP AND THE POWER INFLOW SIGNAL Eli Lilly & Company LLY today experienced a Power Inflow, a significant event for those who follow where ...

THE COOL HOUR - The Cool Hour is the ultimate destination that offers a captivating blend of fashion trends, designer collections, beauty insights, makeup tutorials, and a curated shopping experience ...

Eli Lilly's weight loss drug sales in Q3 weren't ... More importantly, investors need to recognize that the most hectic period of the gold rush for the company's weight loss drug is calming ...

Eli Lilly and Company (NYSE: LLY) announced today detailed results from the Phase 3 SURMOUNT-1 three-year study (176-week treatment period), the longest completed study to date of tirzepatide.

Eli Lilly has seen tremendous growth from its new GLP-1 drugs, which people have been using for weight loss. Sales growth should continue as the company increases production and looks to win ...

Oct 21 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday it sued three medical spas and online vendors for selling products claiming to contain tirzepatide, the main ingredient in its ...

Key drugs from Johnson & Johnson and Eli Lilly stand to bolster their respective cases in competitive dermatology markets with new data readouts. J&J evaluated its Tremfya in patients with low ...